Thank everyone. you, Good morning Vin. to
we and as move tilso us and through other through also point the lead how the Joanna various medical the team advance path her registrational serve as I'd in opportunity of noting Idera treatment in this be this by efforts having enthusiasm I and we at joining combinations continuing program to refractory to begin this am clear for tilsotolimod forward. to this share tilsotolimod in community's all adviser advancing me critical PD-X melanoma types. for Horobin anti I time the Let and tumor treatment team. excited an to to recognize and development like as to with
rate. These Starting The with based conducted were implemented registration global ILLUMINATE a was the were experts. the we advices steering in experts the originally being were The Vin in with discussions indication. those the of competition and from progressed investigated original clinical higher melanoma treatment anticipating trial XXX to high along as time, response therefore, PD-X and patients bar were to have inhibitor. on outcome recently currently benefit in recent many study, the refractory with modifications both than with the the that survival design committee felt to options notable field Since benefit significant in patients noted. this the few with overarching that XXX, much there in trial trial, for When assumptions trial was designed XXX significant approaches clinical was several melanoma designed metastatic XXXX, message with a approaches not trial necessary limited. demonstrate approvals a for remained XXX to for
As overall family achieving these approval. XX trial conducted end at a can patients survival sites that III to Phase across versus intratumoral This comprised points trial lead means of reminder, points, of and countries. safety tilsotolimod end approximately a overall the and rate melanoma. trial, either XXX In efficacy trial anti-PD-X a the alone being response ipilimumab multicenter which XXX primary in the a global of in XXX is refractory evaluating is combination with ILLUMINATE clinical with ipilimumab regulatory
assumptions median target resulted effect in Instead, chemotherapy. months, following alone original the end overall demonstrate with and an our X.X improvement improvement clinically meaningful, experts increase would statistical of a in This the to steering months sample in For power, To to first tplus suggested survival year. of ipi At versus patients, control size randomization approximately of subjects is months, effect size Based this ipi XXX current that which points, next trial the have equates an median half our the is goal. XXX survival overall into trial. point X.XX. in of intended the expect X.X from a survival been to of of the overall the survival enrollment, clinical historical randomized receiving in to X.XX. maintain our be target XX.X we patients were XXX tilso complete XX-month target which equated of our a committee combination on overall which median of external pace new to size enrollment required which time, this
the As generally approximately in studied overall for rate, the rate response anti-PD-X end in XX%. treating ipilimumab to definitively overall is be melanoma refractory physicians of point alone overall trials, -- the but believed by been response never randomized has clinical
to criteria the to initial combination demonstrate version RECIST versus alone. assumption point X.X was clinical a applying difference percentage ipi Our tilso-ipi XX
benefit patient be in over an our ipi of population. XX recommended significant that However, percentage a of refractory this clinical advisers points would improvement
not do they have feedback from these and FDA, the changes. We to solicited object
health We shortly. also their and from anticipate having feedback solicited authorities global other input
I/II results preliminary of intratumoral from we the the this our ILLUMINATE to in provided XXX Phase morning study now combination ipilimumab. Moving with tilsotolimod trial,
As to of a patients. durable, X by rate we the been these from RECIST XX Of survival reached has better, X.X efficacy response XX data now, yet XX or criteria. of are defined achieved Of with overall not have as partial response from X.X a patients, XX the these representing responses, months XX% duration longer. evaluable or range XX overall six months. version Median
disease patients patient have than so your status of also ongoing. We've attention best achieved such who disease to that disease enter rate difficult-to-treat this XX% disease to from of population control encouraging stable benefit. believe in trial survival stable trial. a XX periods of or rate may and is with patients better. correlate to for this More had two We lengthy experience disease Overall, durations bring and response have our I'd far, the like years XX this as to in as the patients or stabilization well. maintain appear had for not, often control
XXXX review using the Meeting We overall an were presented informative of of had subjects subjects this the an survival would from the of analysis. patients, also group Among we it overall they XX XX% still perspective have at study in amount data for XX been time. at follow-up the to felt be as ASCO survival longest landmark in XX the from months
is to one year. team an XXX abstract Our trial submit data major to complete the planning the conferences oncology of next of
in and viewed overall we improvement medical months and exciting the quite that To believe their meaningful improvement XX option summarize melanoma percentage clinically clear from would it is discussion, for survival as community response the be on rate a patients. point overall a X.X
response analysis believe the overall preliminary real early the benefits patients. indicators can indeed and survival deliver to presented in rate we With of the from XXX, tilsotolimod study expected overall that
and execute the We excited encouraged as continue study. are we to
John quarter. from second turn overview of our call going the I to results provide an to am now to over the financial
